We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Microsaic Systems Plc | LSE:MSYS | London | Ordinary Share | GB00BMWC8365 | ORD GBP0.00001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.07 | -6.25% | 1.05 | 1.00 | 1.10 | 1.05 | 1.05 | 1.05 | 1,019,186 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Components, Nec | 1.57M | -2.29M | -0.0128 | -0.82 | 1.88M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/3/2018 20:34 | Lol....watch and weep creep....the smart Money is waiting patiently.....Micros | moneymunch | |
01/3/2018 17:40 | Twice as many sells than buys on 4 trades all day. Not exactly in demand lol. PMSLAU Monkeynuts | stephen2010 | |
28/2/2018 15:56 | For once, some decent buys going through. | k1ngkonggb | |
28/2/2018 15:39 | Wouldn't be surprised to see a pick up in demand for shares between now and Friday's close in anticipation of Monday's Final results.......finger | moneymunch | |
27/2/2018 15:39 | Sooner or later.....this is going to go some....Gla Holders...tick Tock... ;-) 17/12/17 CEO interview Q1: Microsaic recently announced the signing of a research agreement with a global partner in biopharma, can you tell us a little bit more about that? A1: Yes, absolutely so I’ve got to say that we are under strict NDA in this particular case but what I can do is give you some context. Earlier in the year we successfully completed a significant joint feasibility phase to show dedicated at-line mass spec can assess the quality of biologics during the manufacture. I think perhaps the most important aspect of that phase was that we had substantial end-user validation from big pharma and just to say that these are end-users whom our partner has very good global reach. What this new phase is it will bring more end-user validation to the approach, but I think the exciting deliverable is that we’ll be able to provide a lot more technical integration with the partner’s product. So, should this activity be successful, it will take us into the second half of 2018 and then that will proceed a period of productisation. As I said, I can’t give any details yet about the size and timeline for commercialisation, but the opportunity is significant to us, to Microsaic, and delivery is proportionate, I would say, to our timescales. | moneymunch | |
27/2/2018 15:32 | 9/11/17 CEO Interview Q6: Talking about later dates, what have we got to look forward to in terms of the near-future for Microsaic Systems? A6: Well, watch this space. We’ve got some really fantastic enabling technology underway for protein and peptide purification and what we’re doing is taking a much more back-to-basics innovative approach to end user even use, this, along with some great partnerships, will hopefully make 2018 very exciting. We’ve also previously announced that we have a triple quadrupole prototype which will be really a powerful tool in our point of care diagnostics armoury and more of that to follow. | moneymunch | |
27/2/2018 13:13 | Looks like Microsaic have found/recruited the Project Manager responsible for assigned new technology partnership projects...Gla holders...fingers crossed that Monday's Final Results will be well received. :-) Current roles available 27/2/18 Principal Scientist Senior Scientist Senior Software Engineer Product Development Engineer | moneymunch | |
27/2/2018 12:32 | Lol on the contrary Stephanie, you haven't got a clue you sad pathetic creature...ha ha ha....Tick Tock:-) | moneymunch | |
27/2/2018 09:23 | Monkeynuts is going to need botty cream very soon. Been well shafted here. Lmao | stephen2010 | |
27/2/2018 07:28 | Very cheap euclid5, Microsaic's current market cap is £4.9m and they had £4m plus cash in the bank end of June 2017 with operating costs of £1.6m per annum, which suggests they have around £3m cash in the bank now......this coming Monday's final Results will confirm if revenues have picked up, as H2 2017 was anticipated to be much improved on H1 2017 with the roll out of new product and sale of equipment and consumables to their existing OEM's....Gl.....Step | moneymunch | |
26/2/2018 20:14 | we look cheap against Hemo - £21m cap | euclid5 | |
26/2/2018 19:41 | Hows your BLOC doing btw monkeybrain. LMAO | stephen2010 | |
26/2/2018 19:39 | 2.5p tomorrow :) | stephen2010 | |
23/2/2018 17:55 | They've been knocking out their new 4500 MiD (R) as well as equipment and consumables and so maybe better revenues than you think...with any luck!!!... Gl ;-) New product offering and the latest prototype for development, and so nice if they can surprise the market, and great if any other significant new arrives. Gl ;-) Interim Results 28/9/17 Traditional markets The Company is committed to working with its current OEM partners in small molecule detection. These partnerships provide important insights about customer needs and technology enhancements, as well as the capabilities and robustness of the Company's MS instruments in a real-world environment. Although H1 2017 was a very challenging period for revenues we are pleased to see these increasing again through continued close relationships with our partners. H2 2017 revenues from instruments and consumables are anticipated to be above H1 2017 based on current Q3 performance. ........ Post-Period end update -- Appointment of Glenn Tracey as Chief Executive Officer ("CEO") -- Completed development of new extended mass range product offering, the 4500 MiD(R), and first delivery of units to customers -- H2 2017 revenues from instruments and consumables are anticipated to be above H1 2017 based on current performance in Q3. ........ "The Board believes that Microsaic's technology is well placed to exploit opportunities in life sciences and is very encouraged with the progress made so far with one of our global partners, hence we are committed to focusing technical and financial resources on opportunities in bioprocessing." ........ The Company has also developed a working prototype of a miniaturised "triple quadrupole" instrument, and is welcoming interest from partners for further product development and channels to market for this technology, in life science applications. | moneymunch | |
23/2/2018 17:47 | Moneym....here's hoping. Personally, I think we will just hear about slightly improved revenues and continued relationship with current biopharma. Usually, contract news will come further down the line. | k1ngkonggb | |
23/2/2018 17:17 | And that target buy price is and you have to nail it here with one figure!!!! | k1ngkonggb | |
23/2/2018 16:54 | I have a target buy price :) | stephen2010 | |
23/2/2018 16:37 | And when it goes back up, will we see you? | k1ngkonggb | |
23/2/2018 16:35 | 116k sells v 31k buys. 4 trades all day lmao. Not looking good. 2.5p monday and drop to low 2's through the week. Nailed on you just watch :) | stephen2010 | |
23/2/2018 15:43 | Looks like Stephen's trapped his dripping drip in his zip....again....Gla ;-) | moneymunch | |
23/2/2018 15:41 | Only 4 this week, and so no big deal and of no concern imho.....Microsaic is perfectly poised for some upward action on good news. Gl ;-) | moneymunch |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions